Gilmore Neil O’neill Sells 5,124 Shares of Editas Medicine (NASDAQ:EDIT) Stock

Posted by George Bondi on Sep 6th, 2026

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) CEO Gilmore O’neill sold 5,124 shares of Editas Medicine stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $3.04, for a total transaction of $15,576.96. Following the sale, the chief executive officer owned 243,189 shares in the company, valued at $739,294.56. This represents a 2.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Editas Medicine Stock Performance

Shares of EDIT stock opened at $3.23 on Friday. Editas Medicine, Inc. has a 52-week low of $1.66 and a 52-week high of $4.54. The stock has a market cap of $496.06 million, a price-to-earnings ratio of -4.31 and a beta of 2.09. The firm has a fifty day moving average of $3.03 and a 200-day moving average of $2.79.

Editas Medicine (NASDAQ:EDIT – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. The company had revenue of $11.89 million during the quarter, compared to the consensus estimate of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%. On average, sell-side analysts predict that Editas Medicine, Inc. will post -0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

EDIT has been the topic of a number of recent research reports. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. TD Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Wednesday, May 27th. Weiss Ratings upgraded Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, LADENBURG THALM/SH SH started coverage on Editas Medicine in a research note on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Editas Medicine currently has an average rating of “Moderate Buy” and an average price target of $6.00.

View Our Latest Stock Analysis on EDIT

Institutional Investors Weigh In On Editas Medicine

A number of hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors acquired a new position in Editas Medicine in the second quarter valued at about $26,000. Legal & General Group Plc acquired a new stake in shares of Editas Medicine during the second quarter worth approximately $31,000. StoneX Group Inc. acquired a new stake in shares of Editas Medicine during the fourth quarter worth approximately $33,000. Abel Hall LLC bought a new position in shares of Editas Medicine in the first quarter valued at approximately $36,000. Finally, Victory Capital Management Inc. bought a new position in shares of Editas Medicine in the third quarter valued at approximately $36,000. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Company Profile

(Get Free Report)

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.